Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation

BACKGROUND: Janus kinase (JAK) inhibitors, including upadacitinib, have been recently approved for the treatment of moderate-severe atopic dermatitis (AD) and real-world data on upadacitinib effectiveness and safety are limited. This interim analysis aimed to assess effectiveness and safety of upada...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiricozzi, Andrea, Ortoncelli, Michela, Schena, Donatella, Gori, Niccolò, Ferrucci, Silvia Mariel, Babino, Graziella, Napolitano, Maddalena, Fargnoli, Maria Concetta, Stingeni, Luca, Rossi, Mariateresa, Romanelli, Marco, Balestri, Riccardo, Pellegrino, Michele, Parodi, Aurora, Bertoldi, Alberto Maria, Palazzo, Giovanni, Antonelli, Flaminia, Pitino, Annalisa, Tripepi, Giovanni, Fabbrocini, Gabriella, Balato, Anna, Marzano, Angelo Valerio, Girolomoni, Giampiero, Ribero, Simone, Peris, Ketty
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570196/
https://www.ncbi.nlm.nih.gov/pubmed/37322324
http://dx.doi.org/10.1007/s40257-023-00798-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570196/
https://www.ncbi.nlm.nih.gov/pubmed/37322324
http://dx.doi.org/10.1007/s40257-023-00798-0

Ejemplares similares